Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016, Article ID 7826753, 14 pages
http://dx.doi.org/10.1155/2016/7826753
Research Article

Ginsenoside Rg3 Serves as an Adjuvant Chemotherapeutic Agent and VEGF Inhibitor in the Treatment of Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review

1Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medicine Sciences, No. 5 Beixiange, Xicheng District, Beijing 100053, China
2Department of Oncology, Xiyuan Hospital, China Academy of Chinese Medicine Sciences, No. 1 Playground Road, Haidian District, Beijing 100091, China
3Beijing University of Chinese Medicine, No. 11 North Third Ring Road East, Chaoyang District, Beijing 100029, China

Received 21 June 2016; Revised 26 August 2016; Accepted 29 August 2016

Academic Editor: Kenji Watanabe

Copyright © 2016 Tao Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Q. Guo, J. Lin, R. Liu et al., “Review on the applications and molecular mechanisms of xihuang pill in tumor treatment,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 854307, 10 pages, 2015. View at Publisher · View at Google Scholar
  2. Q. Guo, J. Li, and H. Lin, “Effect and molecular mechanisms of traditional Chinese medicine on regulating tumor immunosuppressive microenvironment,” BioMed Research International, vol. 2015, Article ID 261620, 12 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Zhang, H. Lin, M. Yu et al., “Application of TCM and western medical therapeutic evaluation method ologies for the combination treatment with feiliuping extract and chemotherapy in advanced nonsmall-cell lung cancer,” Journal of Traditional Chinese Medicine, vol. 53, no. 5, pp. 403–406, 2012. View at Google Scholar
  4. W. Li, C. Chen, S. M. Saud et al., “Fei-Liu-Ping ointment inhibits lung cancer growth and invasion by suppressing tumor inflammatory microenvironment,” BMC Complementary and Alternative Medicine, vol. 14, article 153, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. J.-W. Kim, S.-Y. Jung, Y.-H. Kwon et al., “Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells,” Cancer Biology and Therapy, vol. 13, no. 7, pp. 504–515, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. M.-W. Chen, L. Yang, L. Ni, and C. Huang, “The effects of 20(R)-Rg3 on lung carcinoma A549 cell line and endogenous VEGF secreted by tumor cells,” Journal of Sichuan University (Medical Science Edition), vol. 37, no. 1, pp. 60–62, 2006. View at Google Scholar · View at Scopus
  7. S. M. Kim, S. Y. Lee, J. S. Cho et al., “Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-κB,” European Journal of Pharmacology, vol. 631, no. 1–3, pp. 1–9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. C. K. Lee, K.-K. Park, A.-S. Chung, and W.-Y. Chung, “Ginsenoside Rg3 enhances the chemosensitivity of tumors to cisplatin by reducing the basal level of nuclear factor erythroid 2-related factor 2-mediated heme oxygenase-1/NAD(P)H quinone oxidoreductase-1 and prevents normal tissue damage by scavenging cisplatin-induced intracellular reactive oxygen species,” Food and Chemical Toxicology, vol. 50, no. 7, pp. 2565–2574, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. Z.-J. Chen, J. Cheng, Y.-P. Huang et al., “Effect of adjuvant chemotherapy of ginsenoside Rg3 combined with mitomycin C and tegafur in advanced gastric cancer,” Zhonghua Wei Chang Wai Ke Za Zhi, vol. 10, no. 1, pp. 64–66, 2007. View at Google Scholar · View at Scopus
  10. P. Lu, W. Su, Z.-H. Miao, H.-R. Niu, J. Liu, and Q.-L. Hua, “Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer,” Chinese Journal of Integrative Medicine, vol. 14, no. 1, pp. 33–36, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and The PRISMA Group, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” PLoS Medicine, vol. 6, no. 7, Article ID e1000097, 2009. View at Publisher · View at Google Scholar
  12. A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” Journal of Clinical Epidemiology, vol. 62, no. 10, pp. e1–e34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M.-W. Chen, Y. Yao, and Z.-H. Shi, “Observation of Curative Effect of Combined 20(R)—Ginsenoside Rg3 with chemotherapy on nonsmall-cell Lung Cancers,” Military Medical Journal of South China, vol. 19, no. 1, pp. 4–6, 2005. View at Google Scholar
  14. S. Chen and R. Li, “Clinical study of gensing Rg3 plus GP regimen in treatment of advanced non-small cell lung cancer,” Contemporary Medicine, vol. 18, no. 31, pp. 1–2, 2012. View at Google Scholar
  15. W. Chen, Y. Tian, Y. Shi et al., “Observation of curative effect of combined traditional chinese medicine and western medicine non-small cell lung cancers,” Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 23, no. 8, pp. 880–881, 2014. View at Google Scholar
  16. L. X. Du, “Clinical observation of adjuvant therapy with gensing Rg3 capsule on advanced non-small cell lung cancer,” Inner Mongol Journal of Traditional Chinese Medicine, vol. 33, no. 34, p. 7, 2014. View at Google Scholar
  17. C. Li, Q. Li, and J. Xu, “Clinical study of GP regimen plus gensing Rg3 in treatment of advanced non-small cell lung cancer,” Cancer Research on Prevention and Treatment, vol. 39, no. 9, pp. 1125–1127, 2012. View at Google Scholar
  18. S. Q. Liu, L. X. Sun, L. Y. Ban et al., “Ginsenoside Rg3 Capsule combined NP regimen in the treatment of advanced non-small cell lung cancer,” Chinese Clinical Oncology, vol. 12, no. 11, pp. 847–849, 2007. View at Google Scholar
  19. S. Liu, R. Zhen, J. Cui et al., “Clinical study of gensing Rg3 capsule plus first-line chemotherapy regimen in treatment of advanced non-small cell lung cancer,” Journal of Clinical Medical, vol. 2, no. 24, pp. 5040–5041, 2015. View at Google Scholar
  20. X. Liu, H. Yang, L. Li et al., “Observation of curative effect of combined gensing Rg3 capsule with chemotherapy on advanced non-small cell lung cancer,” Jilin Medical Journal, vol. 30, no. 19, pp. 2319–2320, 2009. View at Google Scholar
  21. Y. Liu, S. Liu, and C. Xu, “Observation of curative effect of combined gensing Rg3 capsule with adjuvant chemotherapy on advanced non-small cell lung cancer,” Shaanxi Medical Journal, vol. 36, no. 6, pp. 554–556, 2007. View at Google Scholar
  22. M. Pang, “The study of the relation of the level of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor the efficacy of chemotherapy with ShenYi Camplus in advanced NSCLC,” China Dissertation Database, 2012, http://d.wanfangdata.com.cn/Thesis/Y2129524.
  23. C. Qi and H. Zhang, “Ginsenoside Rg3 combined NP regimen in the treatment of advanced non-small cell lung cancer,” Journal of Clinical Medicine in Practice, vol. 15, no. 11, pp. 121–122, 2011. View at Google Scholar
  24. S. Qin, J. Wang, Y. Chen et al., “Clinical study on qi deficiency patients with non-small cell lung cancer (NSCLC) treated by Shenyi capsule,” Chinese Clinical Oncology, vol. 6, no. 4, pp. 327–331, 2001. View at Google Scholar
  25. H. Shao, “Clinical observation on Shenyi capsule combined with docetaxel for elderly patients with advanced non-small cell lung cancer,” Shaanxi Medical Journal, vol. 42, no. 7, pp. 738–740, 2013. View at Google Scholar
  26. M. Shi, J. Feng, L. Pan et al., “Clinical observation of treating non-small cell lung cancer by chemotherapy and shenyi capusle,” Chinese Clinical Oncology, vol. 11, no. 3, pp. 193–197, 2006. View at Google Scholar
  27. Y. Sun, H. Lin, Y. Zhu et al., “A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus gensing Rg3 in the treatment of advanced non-small cell lung cancer patients,” Zhongguo Fei Ai Za Zhi, vol. 9, no. 3, pp. 254–258, 2006. View at Google Scholar
  28. H. Tu, Clinical effect and influence of serum vascular endothelial growth factor on ginsenoside Rg3 plus chemotherapy in non-small cell lung cancer patients [M.S. thesis], Fujian University of Traditional Chinese Medicine, Fuzhou, China, 2008.
  29. Y. Wu, S. Xu, J. Jia et al., “Effect of maintenance treatment with Shenyi capsule on survival period of advanced non-small cell lung cancer patients after induction chemotherapy patients,” Journal of Guangzhou University of Traditional Chinese Medicine, vol. 32, no. 1, pp. 40–43, 2014. View at Google Scholar
  30. Q. Yang, C. Lin, and J. Cui, “Clinical observation of treating elderly patients with advanced non-small cell lung cancer by S-1 and shenyi capusle,” Jilin Medical Journal, vol. 35, no. 25, pp. 5691–5693, 2014. View at Google Scholar
  31. Q. Y. Zhang, X. M. Kang, and M. H. Zhao, “The efficacy analysis of low-dose cyclophosphamide combined with ginsenoside Rg3 on advanced non-small cell lung cancer,” Progress in Modern Biomedicine, vol. 6, no. 2, pp. 50–52, 2006. View at Google Scholar
  32. Z. X. Niu, N. N. Ling, and F. Liang, “Efficacy and safety of Shenyi capsule combined with paclitaxel in treating patient with non-small cell lung cancer,” World Chinese Medicine, vol. 11, no. 7, pp. 1265–1267, 2016. View at Google Scholar
  33. X. Qi, M. Yang, W. Ren et al., “Find duplicates among the PubMed, EMBASE, and cochrane library databases in systematic review,” PLoS ONE, vol. 8, no. 8, Article ID e71838, 2013. View at Publisher · View at Google Scholar
  34. J. F. Tierney, L. A. Stewart, D. Ghersi, S. Burdett, and M. R. Sydes, “Practical methods for incorporating summary time-to-event data into meta-analysis,” Trials, vol. 8, article 16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. C.-S. Tan, D. Gilligan, and S. Pacey, “Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer,” The Lancet Oncology, vol. 16, no. 9, pp. e447–e459, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. R. D. Hall, T. M. Le, D. E. Haggstrom, and R. D. Gentzler, “Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC),” Translational Lung Cancer Research, vol. 4, no. 5, pp. 515–523, 2015. View at Google Scholar
  37. T. Tamura, K. Kurishima, K. Nakazawa, H. Ishikawa, H. Satoh, and N. Hizawa, “Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer,” Oncology Letters, vol. 10, no. 2, pp. 1135–1140, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Salvati, A. Antilli, A. R. Cruciani et al., “Lonidamine plus cyclophosphamide in the treatment of adanced non-small cell lung cancer in the elderly: a phase II study,” Tumori, vol. 81, no. 1, pp. 48–51, 1995. View at Google Scholar · View at Scopus
  39. T. Kasai, Y. Nakamura, M. Fukuda et al., “A phase II study of S-1 for previously untreated elderly patients with advanced non-small cell lung cancer,” Chemotherapy, vol. 61, no. 2, pp. 93–98, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Mamdani, S. I. Jalal, and N. Hanna, “Locally advanced non-small cell lung cancer: optimal chemotherapeutic agents and duration,” Current Treatment Options in Oncology, vol. 16, no. 10, article 47, pp. 1–11, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Ulker, B. B. Duman, B. Sahin, and D. Gumurdulu, “ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine,” Contemporary Oncology, vol. 19, no. 3, pp. 207–213, 2015. View at Google Scholar
  42. H. J. Jiang, H. Wang, S. Y. Wang et al., “Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy,” Molecular Medicine Reports, vol. 11, no. 5, pp. 3523–3532, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Tian, D. Shen, X. Li et al., “Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4,” Oncotarget, vol. 7, no. 2, pp. 1619–1632, 2016. View at Publisher · View at Google Scholar · View at Scopus
  44. D. H. Munn and V. Bronte, “Immune suppressive mechanisms in the tumor microenvironment,” Current Opinion in Immunology, vol. 39, pp. 1–6, 2016. View at Publisher · View at Google Scholar · View at Scopus
  45. Q. Wang, L. Yang, F. Xu, J. Wang, G. Y. An, and Y. M. Ma, “Changes of lymphocyte subgroups in non-small cell lung cancer patients before and during chemotherapy,” Clinical Laboratory, vol. 61, no. 10, pp. 1343–1351, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. J. J. Ma, H. P. Liu, and X. L. Wang, “Effect of ginseng polysaccharides and dendritic cells on the balance of Th1/Th2 T helper cells in patients with non-small cell lung cancer,” Journal of Traditional Chinese Medicine, vol. 34, no. 6, pp. 641–645, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. F. H. Qi, L. Zhao, A. Y. Zhou et al., “The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer,” Bioscience Trends, vol. 9, no. 1, pp. 16–34, 2015. View at Google Scholar
  48. R. H. Wu, Q. Ru, L. Chen, B. M. Ma, and C. Y. Li, “Stereospecificity of ginsenoside Rg3 in the promotion of cellular immunity in hepatoma H22-bearing mice,” Journal of Food Science, vol. 79, no. 7, pp. H1430–H1435, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. L. C. Roudsari and J. L. West, “Studying the influence of angiogenesis in in vitro cancer model systems,” Advanced Drug Delivery Reviews, vol. 97, pp. 250–259, 2016. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Frezzetti, M. Gallo, C. Roma et al., “Vascular endothelial growth factor a regulates the secretion of different angiogenic factors in lung cancer cells,” Journal of Cellular Physiology, vol. 231, no. 7, pp. 1514–1521, 2016. View at Publisher · View at Google Scholar · View at Scopus
  51. P. M. Ellis, “Anti-angiogenesis in personalized therapy of lung cancer,” Advances in Experimental Medicine and Biology, vol. 893, pp. 91–126, 2016. View at Google Scholar
  52. B. Zhou, J. Wang, and Z. Yan, “Ginsenoside Rg3 attenuates hepatoma VEGF overexpression after hepatic artery embolization in an orthotopic transplantation hepatocellular carcinoma rat model,” OncoTargets and Therapy, vol. 7, pp. 1945–1954, 2014. View at Publisher · View at Google Scholar · View at Scopus